Effects of Cardiac Glycosides on Autonomic Nervous System and Endocrine Glands

  • P. H. Joubert
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 56 / 1)


It has been known for over a century that the cardiac glycosides affect the autonomic nervous system and that both the sympathetic and parasympathetic components can be involved. This review will look mainly at the evidence for the autonomic effects of peripherally administered cardiac glycosides as well as postulated mechanisms and will not consider in great detail work concerned with the effects of the cardiac glycosides on the central nervous system.


Autonomic Nervous System Vagal Stimulation Phrenic Nerve Cardiac Glycoside Carotid Sinus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abiko, Y., Mukahira, K., Tanabe, T.: On the role of vagi and sinus nerves in the reflexogenic inhibition of sympathetic discharges induced by strospeside in cats. Jpn. J. Pharmac. 15, 143–148 (1965)CrossRefGoogle Scholar
  2. Anagnoste, B., Goldstein, M: The effects of ouabain on cathecolamine biosynthesis in different areas of rats’ brains. Pharmacologist 9, 210 (1967)Google Scholar
  3. Angelucci, L., Lorentz, G., Baldieri, M.: The relation between noradrenaline content of rabbit heart muscle and the amount of k-strophanthin needed to produce arrhythmias. J. Pharm. Pharmacol. 18, 775–782 (1966)PubMedCrossRefGoogle Scholar
  4. Attree, T., Sawyer, P., Turnbull, M.J.: Interaction between digoxin and tricyclic anti-depressants in the rat. Eur. J. Pharmacol. 19, 294–296 (1972)PubMedCrossRefGoogle Scholar
  5. Basu-Ray, B.N., Dutta, S.N., Pradhan, S.N.: Effects of microinjections of ouabain into certain medullary areas in cats. J. Pharmacol. Exp. Ther. 181 (2) 357–361 (1972)PubMedGoogle Scholar
  6. Bazzi, U., Nicolisi, G.: Modificazioni indotte dalla somministrazione a dosi massive di sostanze a nucleo sterolico sulla eliminazione di steroidi ormonici dell’ urina (11-ossicorticosteroidi, 17-chetosteroidi). II. Azione della digitale. Boll. Soc. Ital. Biol. Sper. 27, 1307–1308 (1951)PubMedGoogle Scholar
  7. Bloch, K.: Zur Pathogenese der Mamma-Hypertrophie bei der Digitalis-Applikation. Z. Kreislaufforsch. 50, 591–595 (1961)Google Scholar
  8. Borison, H.L., Brizzee, K.R.: Morphology of emetic chemoreceptor trigger zone in the cat medulla oblongata. Proc. Soc. Exp. Biol. Med. 77, 38–42 (1951)PubMedGoogle Scholar
  9. Borison, H.L., Wang, S.C.: The vomiting center: Its destruction by radon implantation in dog medulla oblongata. Am. J. Physiol. 166, 712–717 (1951)PubMedGoogle Scholar
  10. Borison, H.L., Wang, S.C.: Physiology and pharmacology of vomitting. Pharmacol. Rev. 5, 193–230 (1953)PubMedGoogle Scholar
  11. Borsch-Galetke, E., Dransfeld, H., Greeff, K.: Specific activity and sensitivity to strophanthin of the Na+ +K+-activated ATP-ase in rats and guinea-pigs with hypoadrenalism. Naunyn Schmiedebergs Arch. Pharmacol. 274, 74–80 (1972)Google Scholar
  12. Boyajy, L.D., Nash, C.B.: Influence of reserpine on arrhythmias, inotropic effects, and myocardial potassium balance induced by digitalis materials. J. Pharmacol. Exp. Ther. 148/ 2, 193–201 (1965)Google Scholar
  13. Boyd, E.M., Brown, M.D., Cassell, W.A.: Delayed vomiting induced in dogs by intramuscular digoxin. J. Pharm. Pharmacol. 11, 742–746 (1959)PubMedCrossRefGoogle Scholar
  14. Busse, W. von, Loennecken, S.J.: Pharmakologische Beeinflußbarkeit reflektorisch-toxischer Digitaliswirkungen (Bradykardie and Erbrechen) über die Herznerven. Naunyn Schmiedebergs Arch. Pharmacol. 220, 232–244 (1953)Google Scholar
  15. Busse, W. von, Göing, H., Lendle, L.: Einfluß des erhöhten Vagustonus auf die Strophanthintoxizität am Herzen. Z. Kreislaufforsch. 44, 604–608 (1955)PubMedGoogle Scholar
  16. Calove, W.L., Whyte, H.M.: Oedema and mammary hypertrophy: a toxic effect of digitalis leaf. Med. J. Aust. 1, 556–557 (1954)Google Scholar
  17. Carpenter, C.C.J., Davis, J.O., Wallace, C.R., Hamilton, W.F.: Acute effects of cardiac glycosides on aldosterone secretion in dogs with hyperaldosteronism secondary to chronic right hart failure. Circ. Res. 10, 178–187 (1962)PubMedGoogle Scholar
  18. Chai, C.Y., Wang, H.H., Hoffmann, B.F., Wang, S.C.: Mechanisms of bradycardia induced by digitalis substances. Am. J. Physiol. 212, 26–34 (1967)PubMedGoogle Scholar
  19. Croxson, M.S., Ibbertson, H.K.: Serum digoxin in patients with thyroid disease. Br. Med. J. 3, 566–568 (1975)PubMedCrossRefGoogle Scholar
  20. Cushman, P.: Inhibition of abdosterone secretion by ouabain in dog adrenal cortical tissue. Endocrinology 84, 808–813 (1969)PubMedCrossRefGoogle Scholar
  21. Dagget, W.M., Weisfeldt, M.L.: Influence of the sympathetic nervous system on the response of the normal heart to digitalis. Am. J. Cardiol. 16, 394–405 (1965)CrossRefGoogle Scholar
  22. Dal-Ri, H., Schmidt, G.: Central and peripheral alteration of respiration by toxic cardiac glycosides in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 239, 158–169 (1960)Google Scholar
  23. Davis, J.O.: Mechanism of salt and water retention in congestive heart failure. Am. J. Med. 29, 486 (1960)PubMedCrossRefGoogle Scholar
  24. Deane, H.W., Gardener, L.I.: Notes and comments: Ouabain and the adrenal cortex. Endocrinology 48, 237–238 (1951)CrossRefGoogle Scholar
  25. Dengler, J.H., Michaelson, I.A., Spiegel, H.E., Titus, E.: The uptake of labelled norepinephrine by isolated brain and other tissues of the cat. Intern. J. Neuropharmacol. 1, 23–28 (1962)CrossRefGoogle Scholar
  26. Doggett, N.S., Case, G.: Some observation on the interaction between cardiac glycosides and reserpine in the heart and central nervous system. Toxicol. Appl. Pharmacol. 33, 87–93 (1975)PubMedCrossRefGoogle Scholar
  27. Doggett, N.S., Spencer, P.S.J.: Pharmacological properties of centrally administered ouabain and their modification by other drugs. Br. J. Pharmacol. 42, 242–253 (1971)PubMedGoogle Scholar
  28. Dresbach, M.: Additional experiments relative to the origin of glycoside emesis using cats and dogs. Am. J. Physiol. 126, 480 (1939)Google Scholar
  29. Dresbach, M.: Further experiments in attempt to locate site of emetic action of digitalis glycosides. J. Pharmacol. Exp. Ther. 91, 307–316 (1947)PubMedGoogle Scholar
  30. Dresbach, M., Waddell, K.C.: Question of reflex vomiting from heart induced by digitalis bodies. J. Lab. Clin. Med. 14, 625–630 (1929)Google Scholar
  31. Dutta, S., Marks, B.H., Schoener, E.P.: Accumulation of radioactive cardiac glycosides by various brain regions in relation to the dysrhythmogenic effect. Br. J. Pharmacol. 59, 101–106 (1977)PubMedGoogle Scholar
  32. Eckstein, J.W., Abboud, F.M., Pereda, S.A.: Hemodynamic responses to administration of acetyl strophanthidin before and after ganglionic blockade in normal dogs and in dogs treated with reserpine. J. Lab. Clin. Med. 58, 814–815 (1961)Google Scholar
  33. Eggleston, C.: The antagonism between atropine and certain central emetics. J. Pharmacol. Exp. Ther. 9, 11–25 (1916)Google Scholar
  34. Eikenburg, D.C., Stickney, J.L.: Inhibition of sympathetic neuronal transport and ouabaininduced cardiac arrhythmias. Res. Commun. Chem. Pathol. Pharmacol. 18 (4), 587–599 (1977)PubMedGoogle Scholar
  35. Farges, J.P., Ollanger, M., Lievre, M., Faucon, G.: Influence of cardiac cholinergie impregnation on the effects of ouabain on atrial and ventricular myocardium. J. Pharmacol. (Paris) 9 (1), 65–75 (1978)Google Scholar
  36. Fawaz, G.: Effect of reserpine and pronethalol on the therapeutic and toxic actions of digitalis in the dog heart-lung preparation. Br. J. Chemother. 29, 302–308 (1967)Google Scholar
  37. Förster, W., Kalsow, H.: Über den unterschiedlichen Einfluß von Dichlorisoproterenol auf den positiv inotropen Effekt verschiedener Digitaliskörper am isolierten Vorhof-Aurikelpräparat des Meerschweinchen. Acta. Biol. Med. Ger. 15, 71–78 (1965)Google Scholar
  38. Förster, W., Sziegoleit, W., Guhlke, I.: Vergleichende Untersuchung einiger extra-cardialer Effekte von herzwirksamen Glykosiden. Arch. Int. Pharmacodyn. 155 (1), 165–182 (1965)PubMedGoogle Scholar
  39. Gaffney, T.E., Kahn, J.B., van Maanen, E.F.: A mechanism of the vagal effect of cardiac glycosides. J. Pharmacol. Exp. Ther. 122, 423–429 (1958)PubMedGoogle Scholar
  40. Gaitondé, B.B., Joglekar, S.N.: Role of catecholamines in the central mechanism of emetic response induced by peruvoside and ouabain in cats. Br. J. Pharmacol. 54 (2), 157–162 (1975)PubMedGoogle Scholar
  41. Gaitondé, B.B., McCarthy, L.E., Borison, H.L.: Central emetic action and toxic effects of digitalis in cats. J. Pharmacol. Exp. Ther. 147 (3), 409–415 (1965)PubMedGoogle Scholar
  42. Gardner, L.I., Berman, H., Deane, H.W.: Metabolic ompetition between descoxycorticosterone acetate and strophanthin-g in the rat. Endocrinology 55, 417–427 (1954)PubMedCrossRefGoogle Scholar
  43. Gillis, R.A.: Cardiac sympathetic nerve activity: Changes induced by ouabain and propranolol. Science 166, 508–510 (1969)PubMedCrossRefGoogle Scholar
  44. Gillis, R.A., Raines, A., Sohn, Y.J., Levitt, B., Standaert, F.G.: Neuroexcitatory effects of digitalis and their role in the development of cardiac arrhythmias. J. Pharmacol. Exp. Ther. 183 (1), 154–158 (1972)PubMedGoogle Scholar
  45. Gillis, R.A., Helke, C.J., Kellar, K.J., Quest, J.A.: Autonomic nervous system actions of cardiac glycosides. Biochem. Pharmacol. 27, 849–856 (1978)PubMedCrossRefGoogle Scholar
  46. Göthert, M.: Der Einfluß von Digitoxin auf die Noradrenalinkonzentration im Myocard. Arzneim. Forsch. 21, 1333–1334 (1971)Google Scholar
  47. Gold, H., Kwit, N.T., Otto, H., Fox, T.: On vagal and extravagal factors in cardiac slowing by digitalis in patients with auricular fibrillation. J. Clin. Invest. 18, 429–437 (1939)PubMedCrossRefGoogle Scholar
  48. Gold, H., Greiner, T., Cattell, M., Modell, W., Gluck, J., Marsh, R., Mathes, S., Hudson, D., Robertson, D., Warshaw, L., Otto, H., Kwit, N., Kramer, M.: Difference in the relation of cardiac to emetic actions in oral and parenteral digitalization. Am. J. Med. 13, 124–144 (1952)PubMedCrossRefGoogle Scholar
  49. Goldstein, M., Ohi, Y., Backstrom, T.: The effect of ouabain on catecholamine biosynthesis in rat brain cortex slices. J. Pharmacol. Exp. Ther. 174, 77–82 (1970)PubMedGoogle Scholar
  50. Gomoll, A.W.: Influence of ouabain on the formation of corticosterone in the rat adrenal gland. J. Pharmacol. Exp. Ther. 156 (2), 300–309 (1967)PubMedGoogle Scholar
  51. Gomoll, A.W., Sherrod, T.R.: Influence of acetylstrophanthin on aldosterone secretion in the intact anesthetized dog. Arch. Int. Pharmacodyn. 150 (3), 469–482 (1964)PubMedGoogle Scholar
  52. Goodman, D.J., Rossen, R.M., Cannom, D.S., Rider, A.K., Harrison, D.C.: Effect of digoxin and atrioventricular conduction: Studies in patients with and without cardiac autonomic innervation. Circulation 51 (2), 251–256 (1975)PubMedGoogle Scholar
  53. Greeff, K.: Mineralstoffwechselwirkung und Toxicität des Strophanthins bei nebennierenlosen Ratten. Arch. Exp. Pathol. Pharmakol. 231, 391–400 (1957)Google Scholar
  54. Greeff, K., Kasperat, H.: Vergleich der neurotoxischen Wirkung von Digitalisglykosiden und Geninen bei intra-cerebraler und intravenöser Injektion an Mäusen, Ratten und Meerschweinchen. Naunyn Schmiedebergs Arch. Pharmacol. 242, 76–89 (1961)Google Scholar
  55. Greeff, K., Westermann, E.: Untersuchung über die muskellähmende Wirkung des Strophanthins. Naunyn Schmiedebergs Arch. Pharmacol. 226, 103–113 (1955)Google Scholar
  56. Greenspan, K., Lord, T.J.: Digitalis and vagal stimulation during atrial fibrillation: effects on atrioventricular conduction and ventricular arrhythmias. Cardiovasc. Res. 7, 241–246 (1973)PubMedCrossRefGoogle Scholar
  57. Guozdjak, J., Niederland, T.R., Honanova, J., Kovacikova, B.: Dynamic investigation of the biochemical changes in the adrenal glands of rats after the administration of digitoxin. Arch. Int. Pharmacodyn. 81 (4), 390–396 (1961)Google Scholar
  58. Halonen, P.I., Kuusisto, A.N., Koskelo, P.: On the effect of strophanthin on thyroid activity. Cardiologia 21, 727–734 (1952)PubMedCrossRefGoogle Scholar
  59. Harvey, S.C.: The effects of ouabain and phenytoin on myocardial noradrenaline. Arch. Int. Pharmacodyn. 213, 222–234 (1975)PubMedGoogle Scholar
  60. Hatcher, R.A., Eggleston, C.: The emetic action of digitalis bodies. J. Pharmacol. Exp. Ther. 4, 113–134 (1912)Google Scholar
  61. Hatcher, R.A., Weiss, S.: Studies on vomiting. J. Pharmacol. Exp. Ther. 22, 139–193 (1923)Google Scholar
  62. Hatcher, R.A., Weiss, S.: Seat of emetic action of digitalis bodies. J. Pharmacol. Exp. Ther. 32, 37–53 (1927)Google Scholar
  63. Heim, F., Bänder, A.: Der Einfluß von Strophanthin auf die Vagus-Erregbarkeit des normalen und geschädigten Warmblüterherzens. Arch. Exp. Pathol. Pharmakol. 212, 456–462 (1951)Google Scholar
  64. Helke, C.J., Souza, J.D., Hamilton, B.L., Morgenroth, V.H., Gillis, R.A.: Evidence for a role of central serotonergic neurones in digitalis-induced cardiac arrhythmias. Nature 263, 246–248 (1976)PubMedCrossRefGoogle Scholar
  65. Hoffmann, G., Lendle, L.: Kritisches zur Digitalisauswertung am Meerschweinchen. Naunyn Schmiedebergs Arch. Pharmacol. 212, 376–385 (1951)Google Scholar
  66. Hoffmann, G., Lendle, L.: Nachweis extrakardialer Digitaliswirkungen an der Ratte. Arch. Exp. Pathol. Pharmakol. 217, 184–193 (1953)Google Scholar
  67. Hohensee, T., Lendle, L.: Über die Frage einer Vaguswirkung von Digitalisglykosiden. Naunyn Schmiedebergs Arch. Pharmacol. 207, 388–408 (1949)Google Scholar
  68. Joubert, P.H.: Digitalis in clinical practice. S. Afr. Med. J. 50, 146–152 (1976)PubMedGoogle Scholar
  69. Joubert, P.H., van der Meer, L.: Digitalis preparations show pharmacodynamic differences with important clinical implications. In: IUPHAR 7th International Congress of Pharmacology, Paris 16–21 July, 1978, Abstracts. Boissien, J.R., Ledrat, P. (eds.), p. 917. Oxford: Pergamon 1978Google Scholar
  70. Kelliher, G.J., Roberts, J.: Effect of 6-hydroxydopamine on ouabain induced arrhythmia. Clin. Res. 20, 857 (1972)Google Scholar
  71. Kien, G.A., Gomoll, A.W., Sherrod, T.R.: Action of digoxin and insulin on transport of glucose through myocardial cell membrane. Proc. Soc. Exp. Biol. Med. 103, 682–685 (1960)PubMedGoogle Scholar
  72. Kirpekar, S.M., Prat, J.C., Yamamoto, H.: Effects of metabolic inhibitors on norepinephrine release from the perfused spleen of the cat. J. Pharmacol. Exp. Ther. 172, 342–350 (1970)PubMedGoogle Scholar
  73. Kitzes-Cohen, R., Neri, A., Schehter, A., Rosenfeld, J.: Estrogen like activity of digoxin, its correlation to vaginal cytology, to digoxin serum levels and Kupperman index. 7th International Congress of Pharmacology, Paris, 16–21 Juli 1978, Abstracts. Boissier, J.R., Lechat, P. (eds.), p. 675. Oxford: Permagon 1978Google Scholar
  74. Koch-Weser, J.: Beta-receptor blockade and myocardial effects of cardiac glycosides. Circ. Res. 28, 109–118 (1971)PubMedGoogle Scholar
  75. Korth, C., Marx, H., Weinberg, S.: Über die Wirkung des Strophanthins auf das Zentralnervensystem. Naunyn Schmiedebergs Arch. Pharmacol. 185, 42–56 (1937)Google Scholar
  76. Kuusisto, A.N., Koskelo, P., Halonen, P.I.: Über die Wirkung von Digitalis und MethylThiourazil auf die Schilddrüse bei gleichzeitiger Zufuhr. Ann. Med. Exp. Fenn. 31, 74–81 (1953)PubMedGoogle Scholar
  77. Kypson, J., Triner, L., Nahas, G.G.: The effects of cardiac glycosides and their interaction with catecholamines on glycolysis and glycogenolysis in skeletal muscle. J. Pharmacol. Exp. Ther. 1641, 22–30 (1968)Google Scholar
  78. Lasché, E.M., Perloff, W.H., Durant, Th. M.: Some aspects of adrenocortical function in cardiac decompensation. Am. J. M.d. Sci. 222, 459–467 (1951)CrossRefGoogle Scholar
  79. Lefer, A.M., Sayers, G.: Antagonism of the inotropic action of ouabain by aldosterone. Am. J. Physiol. 208, 649–654 (1965)PubMedGoogle Scholar
  80. Leitz, F.H., Stefano, F.J.E.: Effect of ouabain and desimipramine on the uptake and storage of norepinephrine and metaraminol. Eur. J. Pharmacol. 11, 278–285 (1970)PubMedCrossRefGoogle Scholar
  81. Lendle, L., Mercker, H.: Extrakardiale Digitaliswirkungen. Ergeb. Physiol. 51, 200–298 (1961)Google Scholar
  82. Lendle, L., Mercker, H., Rohr, H.: Über die Herzvaguswirkung unter dem Einfluß von Digitalglykosiden. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmak. 219, 352–361 (1953)Google Scholar
  83. Lendle, L., Oldenburg, D.: Prüfung extrakardialer Wirkung an der Digitalis-unterempfindlichen Ratte. Arch. Exp. Pathol. Pharmakol. 211, 243–263 (1950)Google Scholar
  84. Lendle, L., Wienke, H.: Zur Frage der Sensibilisierung von Vaguswirkungen auf die Herzfrequenz durch Digitalis. Arch. Exp. Pathol. Pharmakol. 213, 373–386 (1951)CrossRefGoogle Scholar
  85. Levitt, B., Roberts, J.: Effect of quinidine and pronethalol on acetylstrophanthidin-induced ventricular arrhythmia in cats treated with reserpine. Circ. Res. 19, 622–631 (1966)PubMedGoogle Scholar
  86. Levy, J.V., Richards, V.: Inotropic effects of ouabain on rabbit left atria in presence of betaadrenergic blocking drugs. Proc. Soc. Exp. Biol. Med. 119, 278–281 (1965a)PubMedGoogle Scholar
  87. Levy, J.V., Richards, V.: The influence of reserpine pretreatment on the contractile and metabolic effects produced by ouabain on isolated rabbit left atria. J. Pharmacol. Exp. Ther. 1472, 205–211 (1965b)Google Scholar
  88. Le Winn, E.B.: Gynaecomasta during digitalis therapy. N. Engl. J. Med. 248, 316–319 (1953)CrossRefGoogle Scholar
  89. Le Winter, M.M., Crawford, M.H., O’Rourke, R.A., Kaliner, J.S.: The effects of oral propranolol, digoxin, and combination therapy on the resting and exercise electrocardiogram. Am. Heart J. 932, 202–209 (1977)CrossRefGoogle Scholar
  90. Massaro, G.D., Finnerty, F.A., Ryan, M.: The effect of reserpine and digitalis on the heart rate during nor-adrenaline infusion. Am. Heart J. 59, 401–403 (1960)PubMedCrossRefGoogle Scholar
  91. Matheny, J.L., Ahlquist, R.P.: Effect of digitalis on carotid sinus reflex in the rabbit. Fed. Exp. Proc. 32, 717 (1973)Google Scholar
  92. McLain, P.L.: Effects of cardiac glycosides on spontaneous efferent activity in vagus and sympathetic nerves of cats. Int. J. Neuropharm. 8, 379–387 (1969)CrossRefGoogle Scholar
  93. McLain, P.L., Kruse, T.K., Redick, T.F.: The effect of atropine on digitoxin bradycardia in cats. J. Pharmacol. Exp. Ther. 126, 76–81 (1959)PubMedGoogle Scholar
  94. Melville, K.I., Shister, H.E.: General systemic effect and electrocardiographic changes following injections of digitalis glycosides into the lateral ventricle of the brain. Am. Heart J. 53, 425–438 (1957)PubMedCrossRefGoogle Scholar
  95. Metzler, A. von: Über die Wirkung von Strophanthin, Percorten, akuter und chronischer Ammoniakvergiftung auf Herz und Nebennieren von ruhenden und arbeitenden Meerschweinchen. Arch. Kreislaufforsch. 17, 56–71 (1951)CrossRefGoogle Scholar
  96. Metzler, A. von, Greeff, K.: Über den Mechanismus der durch K-Strophanthin verursachten Nebennieren-und Herzhypertrophie. Arch. Exp. Pathol. Pharmakol. 222, 352–359 (1954)Google Scholar
  97. Metzler, A. von, Hergott, J.: Über den Einfluß des Percortens auf toxische Strophanthindosen am Froschherzen in situ. Klin. Wochenschr. 2956, 91–92 (1951)CrossRefGoogle Scholar
  98. Morrow, D.H., Gaffney, T.E., Braunwald, E.: Studies on digitalis. VII. Influence of hyper-and hypothyroidism on the myocardial response to ouabain. J. Pharmacol. Exp. Ther. 140, 324–328 (1963)Google Scholar
  99. Moskopf, E., Sarre, H.: Der Einfluß von Digitoxin auf die Nebenniere des Meerschweinchens im Schwimmversuch. Klin. Wochenschr. 32, 327 (1954)PubMedCrossRefGoogle Scholar
  100. Nadeau, R., de Champlain, J.: Comparative effects of 6-hydroxy-dopamine and of reserpine on ouabain toxicity in the rat. Life Sci. 13, 1753–1761 (1973)PubMedCrossRefGoogle Scholar
  101. Nadeau, R.A., James, T.N.: Antagonistic effects on the sinus node of acetylstrophanthidin and adrenergic stimulation. Circ. Res. 13, 388–391 (1963)PubMedGoogle Scholar
  102. Nakgawa, A., Watanabe, M.: Digitaliswirkungen auf die Cortocosteron-Bildung in der Nebennierenrinde. Naunyn Schmiedebergs Arch. Pharmacol. 254, 355–363 (1966)Google Scholar
  103. Oberg, B., Thorèn, P.: Studies on left ventricular receptors, signalling in non-medullated vagal afferents. Acta Physiol. Scand. 85, 145–163 (1972)PubMedCrossRefGoogle Scholar
  104. Östling, G.: Effect of large digitalis doses on the empty stomach of man. Acta Pharmacol. Toxicol. (Kbn.) 6, 165–168 (1950)CrossRefGoogle Scholar
  105. Pace, D.G., Gillis, R.A.: Neuroexcitatory effects of digoxin in the cat. J. Pharmacol. Exp. Ther. 193, 583–600 (1976)Google Scholar
  106. Pace, D.G., Martin, P.M.: Interactions between digoxin and brief vagal bursts influencing atrioventricular conduction. J. Pharmacol. Exp. Ther. 2053, 657–665 (1978)Google Scholar
  107. Pace, D.G., Thibodeaux, H.: Effect of digoxin on carotid sinus and sympathetic nerve activity. Fed. Proc. 32, 717 (1973)Google Scholar
  108. Pinschmidt, N.W.: Relation of carotid and aortic mechanisms to digitalis emesis. Proc. Soc. Exp. Biol. Med. 61, 7–9 (1946)PubMedGoogle Scholar
  109. Popov, N., Forster, W.: Über den Einfluß verschiedener Digitaliskörper auf die Monaminoxydaseaktivität in Ratten-, Meerschweinchen-und Katzengehirn. Acta Biol. Med. Ger. 17, 221–231 (1966)PubMedGoogle Scholar
  110. Quest, J.A., Gillis, R.A.: Carotid sinus reflex changes produced by digitalis. J. Pharmacol. Exp. Ther. 1772, 650–661 (1971)Google Scholar
  111. Quest, J.A., Thibodeaux, H., Clancy, M.M., Evans, D.E.: Neural mechanisms involved in digitalis-induced bradycardia. Fed. Proc. 32, 717 (1973)Google Scholar
  112. Reiter, M., Noè, J.: Besteht ein Antagonismus zwischen Corticosteron und Strophanthin bezüglich der inotropen Wirkung am Herzmuskel? Naunyn Schmiedebergs Arch. Pharmacol. 238, 75–76 (1960)Google Scholar
  113. Ricken, K.: Interaktionen von Digitalisglykosiden mit östrogenen Hormonen. Inaugural-Dissertation, Universität Düsseldorf 1975Google Scholar
  114. Riggert, H., Schwab, M.: Der Einfluß von Digitoxin auf die Atmung des herzgesunden Menschen. Z. Ges. Exp. Med. 125, 80–92 (1955)PubMedCrossRefGoogle Scholar
  115. Roy, A.R., Chatterjee, M.L.: Effect of ouabain on the catecholamine content of heart and adrenal gland of rabbit. Life Sci. 9, 395–401 (1970)PubMedCrossRefGoogle Scholar
  116. Saxena, P.R., Bhargava, K.P.: The importance of a central adrenergic mechanism in the cardiovascular responses to ouabain. Eur. J. Pharmacol. 31, 332–346 (1975)PubMedCrossRefGoogle Scholar
  117. Schwab, M., Wagner, P.H.: Der Einfluß von K-Strophanthin auf die Atmung des herzgesunden Menschen. Z. Ges. Exp. Med. 129, 28–32 (1957)PubMedCrossRefGoogle Scholar
  118. Seifen, E.: Evidence for participation of catecholamines in cardiac action of ouabain: positive chronotropic effect. Br. J. Pharmacol. 514, 481–490 (1974)Google Scholar
  119. Share, N.N., Chai, C.Y., Wang, S.C.: Emesis induced by intracerebroventricular injections of apomorphine and deslanoside in the dog. Fed. Proc. 23, 349 (1964)Google Scholar
  120. Spann, J.F., Sonnenblick, E.H., Cooper, T., Chidsey, C.A., Willman, V.L., Braunwald, E.: Studies on digitalis XIV: Influence of cardiac norepinephrine stores on the response of isolated heart muscle to digitalis. Circ. Res. 19, 326–331 (1968)Google Scholar
  121. Stickney, K.L.: Differential species sensitivity to the inhibitory effect of cardiac glycosides on 3-H-1-noradrenaline accumulation by tissue slices. Arch. Int. Pharmacodyn. Ther. 224, 215–229 (1976)PubMedGoogle Scholar
  122. Stickney, J.L., Lucchesi, B.R.: The effect of sympatholytic agents on the cardiovascular responses produced by the injection of acetylstrophanthidin into the cerebral ventricles. Eur. J. Pharmacol. 6, 1–7 (1969)PubMedCrossRefGoogle Scholar
  123. Stickney, J.L., Meyers, F.H.: Digitalis toxicity: Development of cardiac arrhythmias in spontaneously breathing vs. artificially respired dogs. Am. Heart J. 854, 501–505 (1973)CrossRefGoogle Scholar
  124. Stoffer, S.S., Hynes, K.M., Jiang, N-S., Ryan, R.J.: Digoxin and abnormal serum hormone levels. J. Am. Med. Assoc. 225, 1643–1644 (1973)CrossRefGoogle Scholar
  125. Sulser, F., Kunz, H.A., Gantenbein, R., Wilbrandt, W.: Zur Frage einer antagonistischen Wirkung zwischen Herzglykosiden und Corticosteroiden auf die Elektrolytausscheidung der Niere. Naunyn Schmiedebergs Arch. Pharmacol. 235, 400–411 (1959)Google Scholar
  126. Swamy, V.C., Hamlin, R.L., Wolf, H.H.: Influence of myocardial catecholamines on the cardiac action of ouabain. J. Pharm. Sci. 510, 1505–1507 (1965)CrossRefGoogle Scholar
  127. Takagi, M., Zanuttini, D., Khalil, E., Bellet, S.: Tolerance of reserpinized dogs to digitalis. Am. J. Cardiol. 15, 203–205 (1965)PubMedCrossRefGoogle Scholar
  128. Tanz, R.D.: The action of ouabain on cardiac muscle treated with reserpine and dichloroisoproterenol. J. Pharmacol. Exp. Ther. 144, 205–213 (1964)PubMedGoogle Scholar
  129. Tanz, T.D., Coram, W.M., Brining, C., Cavaliere, T.: The inotropic action of ouabain in relation to ventricular norepinephirine content. Arch. Int. Pharmacodyn. Ther. 173, 294–305 (1968)PubMedGoogle Scholar
  130. Tatra, G. von, Nissel, W.: Zur Frage der östrogenen Wirksamkeit von Herzglykosiden. Wien. Med. Wochenschr. 24, 460–463 (1969)Google Scholar
  131. Toda, N., West, T.O.: The influence of ouabain on cholinergic responses in the sinoatrial node. J. Pharmacol. Exp. Ther. 1531, 104–113 (1966)Google Scholar
  132. Tsao, D.P.N., King, T.E.: Communications: Effect of cardiac glycosides on 11-hyroxylation of the adrenal system. Arch. Biochem. Biophys. 118, 259–260 (1967)CrossRefGoogle Scholar
  133. Unterman, D., DeGraff, A.C., Kuppermann, H.S.: Effect of hypoadrenalism and excessive doses of desoxycorticosterone acetate upon response of the rat to ouabain. Circ. Res. 3, 280–284 (1955)PubMedGoogle Scholar
  134. Varadi, A., Földes, J.: Serum digoxin in patients with thyroid disease. Br. Med. J. 1, 175 1976.CrossRefGoogle Scholar
  135. Vernikos-Danellis, J., Marks, B.H.: Pituitary inhibitory effects of digitoxin and hydrocortisone. Proc. Soc. Exp. Biol. Med. 109, 10–14 (1962)PubMedGoogle Scholar
  136. Viana, A.P.: Role of adrenergic mechanisms in cardiac and respiratory effects of digoxin. Pharmacology 15, 436–444 (1977)PubMedCrossRefGoogle Scholar
  137. Wang, S.C., Borison, H.L.: A new concept of organization of the central emetic mechanism: recent studies on the sites of action of apomorphine, copper sulfate, and cardiac glycosides. Gastroenterology 221, 1–12 (1952)Google Scholar
  138. Weaver, L.C., Akera, T., Brody, T.M.: Digoxin toxicity: Primary sites of drug action on the sympathetic nervous system. J. Pharmacol. Exp. Ther. 191, 1–9 (1976)Google Scholar
  139. Weinberg, S.J., Haley, T.J.: Centrally mediated effects of cardiac drugs: Strophanthin-K, quinidine, and procainamide. Circ. Res. 3, 103–109 (1955)PubMedGoogle Scholar
  140. Wolff, G.: Über das Verhalten des Blutzuckers nach Strophanthin-Injektionen. Med. Monatsschr. 8, 514–518 (1955)Google Scholar
  141. Wolff, J., Maurey, J.R.: Cardiac glycosides and thyroidal iodide transport. Nature 4640, 957 (1958)CrossRefGoogle Scholar
  142. Zinnith, F.: Die Vaguswirkung auf den Blutdruck unter Rescinnamin und Strophanthin. Acta. Biol. Med. Ger. 3, 82–89 (1959)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • P. H. Joubert

There are no affiliations available

Personalised recommendations